Go to the list of all blogs
Jimmy Landsman's Avatar
published in Blogs
Jul 10, 2026
ProShares UltraPro Dow30 (UDOW) ETF Delivers +15% Gains Over 30 Days on Dow Strength

ProShares UltraPro Dow30 (UDOW) ETF Delivers +15% Gains Over 30 Days on Dow Strength

Key Takeaways

  • UDOW surged approximately 15% over the last 30 days, driven by a powerful rally in the Dow Jones Industrial Average amplified by the fund's 3x daily leveraged structure.
  • Over the last quarter, the ETF has gained roughly 28%, reflecting sustained upward momentum across blue-chip industrial and financial holdings.
  • Financial sector heavyweights — including GS, JPM, and AXP — were primary contributors, supported by a steepening yield curve and improving economic sentiment.
  • Industrial giants such as CAT and HON added further thrust amid infrastructure spending optimism and resilient manufacturing data.
  • As a 3x leveraged product, UDOW magnifies daily index moves, making it highly sensitive to both directional trends and intra-period volatility.

Understanding UDOW's Structure and Market Exposure

UDOW is a leveraged exchange-traded fund managed by ProShares that seeks daily investment results corresponding to three times (3x) the daily performance of the Dow Jones Industrial Average (DJIA). The fund uses derivative instruments — primarily total return swaps and futures contracts — to achieve its magnified exposure. With a gross expense ratio of 0.95%, UDOW is designed for short-term tactical traders rather than long-term buy-and-hold investors, as compounding and volatility decay can cause returns to deviate significantly from 3x the index over holding periods longer than one day.

The underlying DJIA is a price-weighted index comprising 30 large-cap, blue-chip U.S. companies. UDOW's portfolio reflects this composition, with top holdings including GS, CAT, MSFT, AMGN, HD, SHW, MCD, V, AXP, and TRV. Sector-wise, financials represent the largest allocation at approximately 17% of the underlying index, followed by industrials and information technology at roughly 11% and 10%, respectively. Health care, consumer discretionary, and other sectors round out the exposure. This heavy tilt toward cyclical financial and industrial names means UDOW is particularly responsive to shifts in economic growth expectations, interest rate policy, and corporate earnings momentum within these sectors.

Recent Price Performance: 30 Days and the Quarter

Over the last 30 days, UDOW climbed from approximately $61.52 to $70.87, delivering a gain of about 15%. The move was not linear; the ETF experienced several sharp upward thrusts interspersed with brief consolidation periods, characteristic of a trend-driven leveraged instrument during a strong directional rally in the underlying index.

Extending the view to the last quarter, UDOW advanced roughly 28%, rising from around $55.25 in early April to current levels. The quarterly performance underscores a broader rotation into cyclical value stocks and large-cap industrials, with the 3x multiplier significantly enhancing returns during a period of relatively low daily volatility in the Dow. The combination of steady index gains and contained volatility created favorable conditions for a leveraged long fund, allowing the daily compounding effect to work constructively over the multi-month window.

Drivers Behind the 30-Day Advance

The 30-day surge in UDOW was primarily fueled by a broad-based rally in Dow Jones Industrial Average components, amplified threefold by the fund's leveraged structure. Financial stocks were standout performers. GS, the fund's largest single-stock exposure at roughly 7% of the portfolio, rallied on strong investment banking revenue and improving capital markets activity. JPM and AXP also posted robust gains, benefiting from resilient consumer credit trends and a favorable interest rate backdrop that supported net interest margins.

Industrial holdings provided additional thrust. CAT, the second-largest position, advanced amid renewed infrastructure spending optimism and solid global machinery demand. HON and BA contributed as well, with the aerospace and defense segment drawing support from elevated commercial aircraft orders and geopolitical tailwinds.

On the macroeconomic front, easing inflation concerns and growing expectations that the Federal Reserve may be approaching the end of its tightening cycle boosted investor sentiment. The Dow, with its heavy concentration of economically sensitive cyclical stocks, outperformed more technology-heavy indices during this rotation. Inflows into Dow-tracking products and bullish options activity further reinforced the upward momentum, which UDOW's 3x leverage then magnified.

Factors Supporting the Quarterly Results

The quarterly performance reflects a longer-running rotation into value-oriented and cyclical sectors that dominate the Dow Jones Industrial Average. Financials sustained their leadership as the yield curve steepened, improving the profitability outlook for banks and insurers. TRV and AXP benefited from firm insurance pricing and steady consumer spending, respectively.

Industrial and materials names — including CAT, SHW, and MMM — rode a wave of improving manufacturing Purchasing Managers' Index (PMI) data and re-shoring trends that supported domestic production. Health care holdings such as UNH and AMGN provided defensive ballast while still participating in the upside. The quarter also saw relatively subdued daily volatility in the Dow, which helped mitigate the negative compounding effects that can erode leveraged ETF returns during choppy markets. Institutional flows into leveraged long Dow products remained positive, reflecting conviction in the cyclical reflation trade.

UDOW ETF Outlook: Key Factors to Monitor

Looking ahead, several factors will be critical in shaping UDOW's trajectory. The Federal Reserve's interest rate path remains the dominant macro variable; any shift in rate-cut expectations could rapidly reprice financial and industrial holdings that have led the recent rally. Inflation data releases and labor market reports will be closely scrutinized for signs of overheating or cooling that could alter the policy outlook.

At the sector level, the upcoming earnings season for major Dow components — particularly financials like GS and JPM, and industrials like CAT — will test whether current valuations are supported by fundamental performance. Any disappointment in forward guidance could trigger sharp reversals, which would be magnified threefold in UDOW. Conversely, stronger-than-expected results could extend the rally.

Investors should also monitor daily index volatility. As a 3x daily leveraged product, UDOW's returns over multi-day periods are path-dependent; elevated volatility can erode returns even if the underlying index finishes flat or modestly higher. Capital flows into and out of leveraged Dow products, geopolitical developments affecting trade and industrial policy, and commodity price movements — particularly oil, which impacts Dow energy components like CVX — all represent additional factors that could influence performance in the months ahead.

Using Tickeron’s AI Screener for Deeper Market Insights

In my analysis of leveraged products like UDOW, I often turn to Tickeron’s AI Screener to quickly scan for comparable opportunities across sectors and volatility profiles. Tickeron's AI Screener is an advanced stock and ETF discovery platform that empowers investors to scan thousands of securities using a comprehensive set of technical indicators, fundamental metrics, volatility measures, AI-generated signals, and customizable performance filters. The screener helps users identify trending securities, breakout candidates, and new trading opportunities far more efficiently than manual screening. By leveraging pattern recognition, industry-specific filters, and real-time market data, the AI Screener surfaces actionable ideas tailored to an investor's specific strategy — whether momentum-based, value-oriented, or technically driven. For traders seeking to complement their analysis of leveraged products like UDOW with broader market insights, the AI Screener offers a powerful, data-driven starting point.

The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.

Disclaimers and Limitations

Related Ticker: UDOW

Contributor

My name is Jimmy, and I’m a financial analyst. I’m passionate about identifying the most promising ETFs for trading. Every day, I review hundreds of ETFs in search of trading and investment signals based on a variety of factors. I actively use technical analysis to identify short-term opportunities, including channels, indicators, support and resistance levels, and more. I also spend a great deal of time researching ETFs from a long-term investment perspective. My goal is to build a balanced ETF portfolio that combines investment-oriented and speculative ETFs and performs effectively during both market rallies and corrections.


Momentum Indicator for UDOW turns positive, indicating new upward trend

UDOW saw its Momentum Indicator move above the 0 level on July 31, 2026. This is an indication that the stock could be shifting in to a new upward move. Traders may want to consider buying the stock or buying call options. Tickeron's A.I.dvisor looked at 87 similar instances where the indicator turned positive. In of the 87 cases, the stock moved higher in the following days. The odds of a move higher are at .

Price Prediction Chart

Technical Analysis (Indicators)

Bullish Trend Analysis

The Moving Average Convergence Divergence (MACD) for UDOW just turned positive on August 03, 2026. Looking at past instances where UDOW's MACD turned positive, the stock continued to rise in of 55 cases over the following month. The odds of a continued upward trend are .

UDOW moved above its 50-day moving average on July 30, 2026 date and that indicates a change from a downward trend to an upward trend.

Following a 3-day Advance, the price is estimated to grow further. Considering data from situations where UDOW advanced for three days, in of 352 cases, the price rose further within the following month. The odds of a continued upward trend are .

The Aroon Indicator entered an Uptrend today. In of 294 cases where UDOW Aroon's Indicator entered an Uptrend, the price rose further within the following month. The odds of a continued Uptrend are .

Bearish Trend Analysis

The 10-day RSI Indicator for UDOW moved out of overbought territory on August 06, 2026. This could be a bearish sign for the stock. Traders may want to consider selling the stock or buying put options. Tickeron's A.I.dvisor looked at 37 similar instances where the indicator moved out of overbought territory. In of the 37 cases, the stock moved lower in the following days. This puts the odds of a move lower at .

The Stochastic Oscillator demonstrated that the ticker has stayed in the overbought zone for 4 days. The longer the ticker stays in the overbought zone, the sooner a price pull-back is expected.

Following a 3-day decline, the stock is projected to fall further. Considering past instances where UDOW declined for three days, the price rose further in of 62 cases within the following month. The odds of a continued downward trend are .

UDOW broke above its upper Bollinger Band on August 03, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.

Notable companies

The most notable companies in this group are NVIDIA Corp (NASDAQ:NVDA), Apple (NASDAQ:AAPL), Microsoft Corp (NASDAQ:MSFT), Amazon.com (NASDAQ:AMZN), JPMorgan Chase & Co (NYSE:JPM), Walmart (NASDAQ:WMT), VISA (NYSE:V), Johnson & Johnson (NYSE:JNJ), Cisco Systems (NASDAQ:CSCO), Caterpillar (NYSE:CAT).

Industry description

The investment seeks daily investment results, before fees and expenses, that correspond to three times (3x) the daily performance of the Dow Jones Industrial Average®. The fund invests in financial instruments that ProShare Advisors believes, in combination, should produce daily returns consistent with the Daily Target. The index is designed to measure the performance of some of the largest U.S. companies. Under normal circumstances, the fund will obtain leveraged exposure to at least 80% of its total assets in components of the index or in instruments with similar economic characteristics. The fund is non-diversified.

Market Cap

The average market capitalization across the ProShares UltraPro Dow30 ETF is 800.8B. The market cap for tickers in the group ranges from 61.86B to 5.42T. NVDA holds the highest valuation in this group at 5.42T. The lowest valued company is NKE at 61.86B.

High and low price notable news

The average weekly price growth across all stocks in the ProShares UltraPro Dow30 ETF was 13%. For the same ETF, the average monthly price growth was 30%, and the average quarterly price growth was 101%. AMZN experienced the highest price growth at 16%, while AAPL experienced the biggest fall at -6%.

Volume

The average weekly volume growth across all stocks in the ProShares UltraPro Dow30 ETF was -29%. For the same stocks of the ETF, the average monthly volume growth was -17% and the average quarterly volume growth was -60%

Fundamental Analysis Ratings

The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows

Valuation Rating: 56
P/E Growth Rating: 52
Price Growth Rating: 39
SMR Rating: 34
Profit Risk Rating: 45
Seasonality Score: -37 (-100 ... +100)
View a ticker or compare two or three
UDOW
Daily Signal:
Gain/Loss:
Interact to see
Advertisement
A.I.Advisor
published price charts
Last 5 trading days
A.I. Advisor
published General Information

General Information

Category Trading

Profile
Details
Category
Trading--Leveraged Equity
Address
ProShares Trust7501 Wisconsin Avenue,Suite 1000Bethesda
Phone
N/A
Web
www.proshares.com
Interact to see
Advertisement
Novartis (NVS) reports Q4/FY 2025 earnings on February 4, 2026, with consensus calling for ~$1.99 EPS on ~$13.7 billion in revenue. Sanofi (SNY) delivered strong FY 2025 results on January 29, reporting €43.6 billion in sales (+9.9% CER) and 15% business EPS growth.
Novo Nordisk (NVO) reports Q4 2025 earnings on February 4, 2026, with consensus estimates of $11.96 billion in revenue and $0.89 EPS, reflecting a moderation in GLP-1 growth. Eli Lilly (LLY) is expected to report around the same time, with projections of $17.87 billion in revenue and $6.99 EPS, driven by continued volume gains from Mounjaro and Zepbound.
MUFG is expected to report Q3 FY2026 EPS of about $0.30, broadly in line with its recent pattern of earnings beats.
Banco Santander (SAN) reports Q4 2025 earnings on February 4, 2026, following record nine-month attributable profit of €10.3 billion, up 11% year over year.
Uber (UBER) reports Q4 2025 earnings on February 4, 2026, with consensus estimates of $0.78 EPS and $14.32 billion in revenue, up about 20% year over year.
Qualcomm’s Q1 FY2026 report, covering the period ended December 28, 2025, arrives amid a pivotal shift in the semiconductor landscape. While handset growth moderates, the company is expanding in automotive, IoT, and AI-enabled devices.
UBS Group AG reports Q4 2025 earnings on February 4, 2026, with consensus EPS ranging $0.25–$0.67 and revenue around $11.62 billion, down YoY. HSBC Holdings plc reports Q4 earnings on February 25, 2026, with consensus EPS ~$1.57; Q3 showed resilient net interest income despite $1.4B in legal provisions.
Boston Scientific’s Q4 caps a transformative year, driven by ~15.5% organic growth from WATCHMAN, FARAPULSE electrophysiology, and MedSurg expansions. As a leader in minimally invasive devices, BSX’s results set the benchmark against Medtronic and Stryker—diversified medtech giants navigating tariffs, procedural rebounds, and innovation.
Arm, the leading provider of energy-efficient processor designs powering over 99% of smartphones and expanding into AI data centers, faces high scrutiny in Q3 FY2026 (ending Dec 31, 2025). After a strong Q2 with record royalty and licensing revenue, investors are focused on whether AI demand will continue to drive robust growth.
CME Group (CME): Q4 2025 earnings due February 4, 2026; consensus expects adjusted EPS $2.75 and revenue ~$1.6B. S&P Global (SPGI): Q4 2025 earnings due February 10, 2026; Q3 posted EPS $4.73 and 9% revenue growth, driven by Ratings, Indices, and Market Intelligence.
Datadog (DDOG) has come under pressure in recent sessions as volatility across the software sector weighs on sentiment ahead of earnings. Trading in the $108–120 range following a pullback from highs near $200, the stock reflects a disconnect between near-term market caution and resilient underlying fundamentals.
Starbucks shares have shown renewed strength in recent trading, rebounding from earlier lows within a 52-week range of $75.50 to $117.46. The recovery reflects improving comparable sales trends and a return to transaction growth, suggesting early progress from operational initiatives aimed at reconnecting with customers.
DoorDash holds a Strong Buy consensus from 33 analysts, with an average 12-month price target of $280.82, implying more than 40% upside from recent trading levels.
Amazon’s Q4 report capped a strong year marked by accelerating cloud growth, steady retail execution, and expanding advertising profitability. The results reinforced Amazon’s positioning as a core beneficiary of enterprise AI demand, particularly through AWS, while highlighting improving operating leverage across the broader business.
ConocoPhillips reported Q4 2025 adjusted EPS of $1.02, below consensus of $1.08, driven by weaker realized commodity prices.
ICE reported Q4 2025 net revenues of $2.5 billion, up 8% year-over-year, capping 20 consecutive years of record annual revenues at $9.9 billion.
Eli Lilly’s Q4 results highlight explosive growth from GLP-1 therapies, cementing leadership in obesity and diabetes. The company’s strong revenue beat and robust 2026 guidance illustrate high-growth pharma dynamics. Johnson & Johnson, in contrast, exemplifies a diversified healthcare strategy, combining pharmaceuticals, MedTech, and consumer health for steady expansion.
Eli Lilly (LLY), AbbVie (ABBV), and Merck (MRK) all reported strong Q4 2025 earnings, but the market reacted differently to each, reflecting variations in growth profiles, product concentration, and sector dynamics. AbbVie delivered Q4 revenue of $16.62 billion, up 10% year-over-year, with full-year revenue reaching $61.2 billion, an 8.6% increase. Adjusted EPS came in at $2.71, surpassing consensus, though shares dipped following the report amid ongoing Humira concerns
Novo Nordisk (NVO) reported Q4 2025 EPS of $1.02, surpassing estimates of $0.92, with revenue of $12.53B vs $11.99B expected. Full-year 2025 sales rose 10% at constant exchange rates (CER) to DKK 309B, but 2026 guidance anticipates a 5–13% decline at CER due to pricing pressures. Novartis (NVS) posted Q4 core EPS of $2.03, beating $1.99 estimates; net sales of $13.34B slightly missed consensus. FY sales grew 8%, with core EPS up 17% to $8.98.
MUFG (Mitsubishi UFJ Financial Group) posted Q3 FY2026 profits of ¥1.81 trillion, up 3.7% YoY, on track for its full-year target of ¥2.1 trillion. HSBC is set to report Q4 FY2025 earnings on Feb 25, 2026, with consensus EPS around $1.60; recent quarters showed resilient net interest income (NII) supported by Asia wealth growth.